Group 1 - The core viewpoint of the article highlights the recent board meeting of Jiuan Medical, where the company discussed the change in the purpose of share repurchase and cancellation [1] - For the first half of 2025, Jiuan Medical's revenue composition is as follows: medical devices account for 87.74%, internet medical products and services account for 6.57%, retail business accounts for 5.03%, and other industries account for 0.66% [1] - As of the report date, Jiuan Medical has a market capitalization of 18.3 billion yuan [1]

Core Viewpoint - The company plans to change the purpose of repurchasing 9,106,900 shares, which were bought back on August 29, 2023, to "cancel and reduce the company's registered capital" [1] Group 1: Share Repurchase and Capital Reduction - The number of shares to be canceled is 9,771,900, accounting for 2.06% of the company's current total share capital [1] - After the cancellation, the total share capital will decrease from 475 million shares to 465 million shares [1] - This move aims to actively maintain the company's market value and enhance shareholder returns [1] Group 2: Financial Impact - The change in the purpose of the repurchased shares and the cancellation will not have a significant impact on the company's financial condition, operating results, or future development [1] - There will be no change in the controlling shareholder or actual controller of the company as a result of this action [1]

证券代码：002432 证券简称：九安医疗 公告编号：2025-063 天津九安医疗电子股份有限公司 上述回购股份方案已于 2023 年 11 月 17 日实施完毕，公司累计通过回购专 用证券账户以集中竞价交易方式回购股份数量为 27,164,101 股，占公司当时总股 本的 5.57%，最高成交价为 37.99 元/股，最低成交价为 35.53 元/股，成交总金额 为人民币 999,996,846.14 元（含交易费用等）。具体详见公司披露于巨潮资讯网 的《关于公司股份回购完成暨股份变动的公告》（公告编号：2023-071）。 二、本次变更回购股份用途并注销的原因 公司于 2025 年 9 月 5 日召开第六届董事会第二十五次会议，审议并通过了 《关于变更部分回购股份用途并注销的议案》，为积极维护公司市值，增强上市 公司股东回报，董事会同意将该次回购股份实施完毕后，存放于回购专用账户中 原计划用于维护公司价值及股东权益，并可通过集中竞价交易方式减持的 9,771,882 股股份用途变更为"用于注销并减少公司注册资本"，占公司目前总股 本的 2.06%，剩余库存股用途保持不变，该事项尚需股东大会审议通过方可实 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-064 天津九安医疗电子股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年9月5日召开 了第六届董事会第二十五次会议，会议决定于2025年9月22日召开公司2025年第 三次临时股东大会，本次股东大会采用现场投票及网络投票相结合的方式进行。 根据《公司章程》的规定，现将召开本次股东大会的有关事项公告如下： 一、召开会议基本情况 1、股东大会届次：2025年第三次临时股东大会 2、会议召集人：公司董事会 3、公司第六届董事会第二十五次会议审议通过了《关于召开2025年第三次 临时股东大会的议案》，本次股东大会会议召开符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 4、会议召开的日期和时间 （1）现场会议时间：2025年9月22日下午14:00 （2）网络投票时间：2025年9月22日 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年9月22日上 午9: ...

具体内容详见公司同日披露于公司指定信息披露媒体《证券时报》和巨潮资 讯网(http://www.cninfo.com.cn)的《关于变更部分回购股份用途并注销暨减少注 册资本的公告》（公告编号：2025-063）。 天津九安医疗电子股份有限公司 第六届监事会第二十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年9月2 日以书面方式发出召开第六届监事会第二十次会议的通知，会议于2025年9月5 日在公司会议室以现场表决方式召开。本次会议由公司监事会主席姚凯先生主持， 会议应参加的监事3名，实际参加的监事3名，会议的召集、召开与表决程序符合 《公司法》等法律法规及《公司章程》的规定。与会监事就会议议案进行了审议 及表决，通过了如下议案： 一、以3票同意、0票反对、0票弃权的表决结果，审议通过了《关于变更部 分回购股份用途并注销的议案》 经审议，监事会认为本次变更部分回购股份用途符合《上市公司股份回购规 则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定， ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-061 一、以6票同意、0票反对、0票弃权的表决结果，审议通过了《关于变更部 分回购股份用途并注销的议案》 为积极维护公司市值，增强上市公司股东回报，结合公司实际情况，董事会 同意将 2023 年度回购股份实施完毕后，存放于回购专用账户中原计划用于维护 公司价值及股东权益，并可通过集中竞价交易方式减持的 9,771,882 股股份用途 变更为"用于注销并减少公司注册资本"。 该事项尚需股东大会审议通过方可实施。公司董事会提请股东大会授权公司 管理层办理股份注销等相关手续。 具 体 内 容 详 见 公 司 同 日 刊 登 于 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的《关于变更部分回购股份用途并注销暨减少注册 资本的公告》（公告编号：2025-063）。 天津九安医疗电子股份有限公司 第六届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年9 ...

Group 1 - The issuance of the 2025 first phase technology innovation bond by Tianjin Jiuan Medical Electronics Co., Ltd. marks a significant milestone as it is the first technology innovation bond for private technology enterprises in Tianjin, with a total issuance scale of 1.05 billion yuan [1] - The bond issuance is a key initiative by Industrial Bank Tianjin Branch to support the development of private technology enterprises, aligning with the central financial work conference's spirit and promoting financial resources towards "early, small, long-term, and hard technology" sectors [1][3] - The funds raised from the bond will be primarily allocated to upgrading smart medical devices and building a digital platform for chronic disease management, enhancing the company's technological leadership in the industry [2] Group 2 - Jiuan Medical has established a strong foundation for the bond issuance through its commitment to technological innovation, with a dedicated R&D team and significant investment in research, resulting in multiple national patents and industry awards [2] - The company's iHealth series of smart medical devices integrates mobile internet technology with precise detection functions, covering various health monitoring scenarios and achieving a market presence in over 100 countries [2] - The company has developed an innovative "O+O" model for diabetes management, providing comprehensive services from screening to long-term health management, having served over 500,000 chronic disease patients [2]

Core Insights - Beijing Qiji Chuangtan Phase II Venture Capital Center (Limited Partnership) has undergone a business change, adding Xiaomi's subsidiary fund Huanxing Venture Capital Co., Ltd. and Jiuan Medical (002432) as shareholders [1] Group 1 - The company was established in 2022 with a registered capital of 906 million yuan [1] - The business scope includes private equity fund activities such as equity investment, investment management, and asset management [1]

Group 1 - Konomei (Beijing) Technology Co., Ltd. has completed several million yuan A+ round financing, led by Jiuan Medical, to accelerate commercialization and continue independent research and innovation [1] - The company, founded in 2019, focuses on the independent research and industrialization of ultra-high performance liquid chromatography (UHPLC) technology, with the core founding team having an average of nearly 20 years of experience in the life science instrument field [1] - As of April 2025, Konomei has applied for over 30 patents and software copyrights, including 6 invention patents and 14 utility model patents, along with multiple proprietary technologies [1] Group 2 - Jiuan Medical's chairman, Liu Yi, emphasizes the company's commitment to discovering and partnering with practical enterprises that can address industry pain points and lead industrial upgrades [2] - Jiuan Medical focuses on two core opportunities: deepening independent research around the "Stanford model" to activate the "engineer dividend" and seizing the wave of domestic scientific instrument production and policy support to promote import substitution in the global market [2] - Konomei's breakthroughs in the ultra-high performance liquid chromatography field have disrupted China's long-standing reliance on imports in the high-end market of this sector [2]

Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed several million yuan in A+ round financing, led by Jiuan Medical, to accelerate commercialization and continue independent research and innovation [3] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography as the leading product [3] - Konomai, established in 2019, focuses on the independent research and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [3][4] - The company has achieved a 95% localization rate for product components as of 2022, with a full series of UHPLC products developed [4] Company Performance - Since the start of its commercialization in 2023, Konomai has maintained an annual sales growth rate exceeding 50%, with overseas market growth surpassing 80% [5] - The company has expanded its customer base to hundreds across over 20 countries and regions, covering various fields such as drug analysis, biosynthesis, academic research, food safety, and environmental protection [5] Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the focus on practical enterprises that can address industry pain points and lead industrial upgrades, highlighting Konomai's role in breaking the long-standing reliance on imports in the high-end market of ultra-high-performance liquid chromatography [6]